Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401

NCT02166255 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT02166255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02166255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2014
Completion date
May 31, 2016
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent melanoma, recurrent pancreatic cancer, recurrent renal cell cancer, stage iii pancreatic cancer, stage iii renal cell cancer, stage iiia melanoma, stage iiib melanoma, stage iiic melanoma, stage iv melanoma, stage iv pancreatic cancer, stage iv renal cell cancer, unspecified adult solid tumor, protocol specific